Finally, a retrospective cohort study compared 1775 matched pairs of SGLT2i users and nonusers with SLE and type 2 diabetes from the TriNetX database and found that use of SGLT2i was associated with significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use 8 9,10
Chosen by 80 000 customers worldwide, were one of the fastest growing peptide companies in the UK
Conclusions - The prevalence of CKD is high in DM2 and DKD is associated with increased cardiovascular risk, mortality and progression to end-stage CKD, requiring early and intensive treatment to minimize these complications
Clinical trials have examined whether semaglutide increases, decreases, or has a neutral effect on blood pressure
Clinical studies of this product are required before claims can be supported
The incidence of MASLD has been on the rise concurrently with the obesity pandemic, and it is still rising in countries with an increased sedentary lifestyle and poor dietary choices
